T0	Population 30720 30751	appropriate patient populations
T1	OutcomeMeasures 30756 30772	outcome measures
T2	Generalization 30805 30913	Whether quilizumab could have a clinically meaningful effect in another subgroup of allergic asthma patients
T3	StudyDuration 30917 30979	whether a treatment period beyond 36Â weeks would show efficacy
